Posted by Michael Wonder on 31 Jan 2017
Patients battling deadly ovarian, lung cancer to have affordable access to new drugs
31 January 2017 - Sick patients battling deadly cancers will have affordable access to new drugs which usually cost more than $100,000 per treatment.
Two new medicines used to treat serious ovarian and lung cancer have been listed on the Pharmaceutical Benefits Scheme costing the Federal Government more than $176 million over the next five years.
Over the next five years, more that 1100 women battling high-grade ovarian cancer will be able to buy Olaparib which usually costs more than $100,000 per treatment, for just $38.80 or just over $6 for those on concession.
